Targeted Oncology

FDA Grants Breakthrough Designation for Bezuclastinib in GIST

The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in ...
CURE

FDA Grants Designation to Bezuclastinib Combo in Advanced GIST

The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal ...

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus ...
Cure Today

Diagnosing GIST: Key Challenges and Treatment Insights

Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions. Dr. Breelyn Wilky, an associate professor of ...
KARE 11

GIST Cancer Research Fundraiser

BLOOMINGTON, Minn.--The GIST Cancer Research Fundraiser is Friday, August 4 at the Knights of Columbus from 7:00 p.m.-10:00 p.m. Proceeds provide support to those with Gastro Intestinal Stromal Tumors ...